The Dairy Authority, Greeley, CO 80634, USA.
J Dairy Sci. 2012 Nov;95(11):6677-86. doi: 10.3168/jds.2012-5605. Epub 2012 Aug 29.
The aim of this field study was to compare the efficacy and cost of 2 commercially available oral rehydration therapy (ORT) solutions in treating dairy calves with naturally acquired diarrhea. A total of 1,349 newborn Holstein-Friesian calves were prospectively enrolled in the study. Calves were housed in individual hutches and fed a mixture of pasteurized hospital milk and an all-milk protein milk replacer twice per day. Calves were monitored twice each day from d 2 of life until 30 d of age for the presence or absence of diarrhea, and were assigned a fecal score and a hydration score at each examination. Calves that developed mild to severe diarrhea that did not need intravenous fluids and did not have clinical evidence of concurrent disease (n = 360) were assigned randomly to receive 1 of 2 commercial ORT solutions: a hypertonic alkalinizing ORT containing lecithin-coated citrus fibers (Diaque, group D, n = 180; Boehringer Ingelheim, Ingelheim, Germany), and an isotonic nonalkalinizing ORT (RE-SORB, group R, n = 180; Pfizer Animal Health, New York, NY) for 2 to 8d; the duration of treatment depended on whether diarrhea was still present. No significant differences were observed in mortality rates or treatment failure rates between the 2 treatment groups. Fecal consistency returned to normal more quickly in group D calves than in group R calves; consequently, group D calves were treated for 1d less than were group R calves. The increase in body weight after 4d of treatment was larger in group D than in group R. The average daily gain from birth to weaning in calves that did not develop concurrent disease (such as pneumonia) during the study period tended to be higher in group D calves (0.53±0.11 kg/d) than in group R calves (0.51±0.09 kg/d). The smaller number of treatments at a lower cost per treatment produced a cost advantage of $4.82 per treated calf in group D calves compared with group R calves. Our findings support the concept that milk should continue to be fed to diarrheic calves that are being administered an ORT solution in order to maintain growth.
本现场研究旨在比较两种市售口服补液盐(ORT)溶液在治疗自然感染腹泻的奶牛犊牛中的疗效和成本。共有 1349 头新生荷斯坦-弗里森奶牛犊牛前瞻性纳入本研究。犊牛被安置在单独的畜栏中,每天两次喂食巴氏消毒的医院牛奶和全牛奶蛋白代乳料的混合物。从出生后第 2 天到 30 天,每天监测犊牛两次,以确定其是否存在腹泻,并在每次检查时对其粪便评分和水合评分进行评估。患有轻度至重度腹泻但无需静脉补液且无合并症临床证据的犊牛(n=360)被随机分配接受 2 种市售 ORT 溶液中的 1 种:含有卵磷脂包被的柑橘纤维的高渗碱性 ORT(Diaque,D 组,n=180;Boehringer Ingelheim,Ingelheim,德国)和等渗非碱性 ORT(RE-SORB,R 组,n=180;辉瑞动物保健,纽约州,NY)治疗 2 至 8 天;治疗持续时间取决于腹泻是否仍存在。在死亡率或治疗失败率方面,两组治疗方法之间没有观察到显著差异。D 组犊牛粪便稠度恢复正常的速度快于 R 组犊牛,因此 D 组犊牛的治疗时间比 R 组犊牛少 1 天。治疗 4 天后,D 组犊牛的体重增加量大于 R 组犊牛。在研究期间未发生肺炎等合并症的犊牛(如肺炎)从出生到断奶的平均日增重,D 组犊牛(0.53±0.11kg/d)高于 R 组犊牛(0.51±0.09kg/d)。D 组犊牛每治疗一头的治疗次数较少,且每治疗一次的成本较低,因此与 R 组犊牛相比,D 组犊牛每治疗一头的成本优势为 4.82 美元。我们的研究结果支持这样一种观点,即应继续向接受 ORT 溶液治疗的腹泻犊牛提供牛奶,以维持其生长。